STOCK TITAN

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Puma Biotechnology (NASDAQ:PBYI) announced it will host a conference call on Thursday, November 7, 2024, at 1:30 p.m. PST/4:30 p.m. EST to discuss its third quarter 2024 financial results. Participants can join via phone using 1-877-709-8150 (domestic) or 1-201-689-8354 (international). A live webcast and presentation slides will be available on the company's website, with a replay accessible for 90 days.

Puma Biotechnology (NASDAQ:PBYI) ha annunciato che ospiterà una conferenza telefonica il giovedì 7 novembre 2024, alle 13:30 PST/16:30 EST per discutere i risultati finanziari del terzo trimestre 2024. I partecipanti possono unirsi telefonicamente utilizzando il numero 1-877-709-8150 (domestico) o 1-201-689-8354 (internazionale). Sarà disponibile un webcast in diretta e le diapositive di presentazione sul sito web dell'azienda, con una riproduzione accessibile per 90 giorni.

Puma Biotechnology (NASDAQ:PBYI) anunció que realizará una llamada de conferencia el jueves 7 de noviembre de 2024, a la 1:30 p.m. PST/4:30 p.m. EST para discutir sus resultados financieros del tercer trimestre de 2024. Los participantes pueden unirse por teléfono utilizando el número 1-877-709-8150 (nacional) o 1-201-689-8354 (internacional). Se dispondrá de una transmisión en vivo y diapositivas de presentación en el sitio web de la empresa, con una repetición accesible durante 90 días.

Puma Biotechnology (NASDAQ:PBYI)는 2024년 11월 7일 목요일 오후 1:30 PST/오후 4:30 EST에 2024년 3분기 재무 결과를 논의하기 위한 컨퍼런스 콜을 개최한다고 발표했습니다. 참가자는 1-877-709-8150(국내) 또는 1-201-689-8354(국제)를 사용하여 전화로 참여할 수 있습니다. 회사 웹사이트에서 라이브 웹캐스트와 발표 슬라이드를 사용할 수 있으며, 90일 동안 다시 시청할 수 있습니다.

Puma Biotechnology (NASDAQ:PBYI) a annoncé qu'elle organisera une conférence téléphonique le jeudi 7 novembre 2024 à 13h30 PST/16h30 EST pour discuter de ses résultats financiers du troisième trimestre 2024. Les participants peuvent se joindre par téléphone en utilisant le numéro 1-877-709-8150 (national) ou 1-201-689-8354 (international). Un webinaire en direct et les diapositives de présentation seront disponibles sur le site de l'entreprise, avec une rediffusion accessible pendant 90 jours.

Puma Biotechnology (NASDAQ:PBYI) hat angekündigt, dass am Donnerstag, den 7. November 2024, um 13:30 Uhr PST/16:30 Uhr EST eine Telefonkonferenz stattfinden wird, um die Finanzergebnisse des dritten Quartals 2024 zu besprechen. Teilnehmer können sich telefonisch unter 1-877-709-8150 (national) oder 1-201-689-8354 (international) einwählen. Ein Live-Webcast und Präsentationsfolien werden auf der Website des Unternehmens verfügbar sein, mit einer Wiederholung, die 90 Tage lang zugänglich ist.

Positive
  • None.
Negative
  • None.

LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, November 7, 2024, following the release of its third quarter 2024 financial results.

The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available shortly after completion of the call and will be archived on Puma’s website for 90 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc.

In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung 1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer.

Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com.

Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500

info@pumabiotechnology.com

ir@pumabiotechnology.com

David Schull or Olipriya Das, Russo Partners, +1 212 845 4200

david.schull@russopartnersllc.com

olipriya.das@russopartnersllc.com

Source: Puma Biotechnology, Inc.

FAQ

When will Puma Biotechnology (PBYI) release Q3 2024 earnings?

Puma Biotechnology will release its third quarter 2024 financial results on Thursday, November 7, 2024, followed by a conference call at 1:30 p.m. PST/4:30 p.m. EST.

How can I access Puma Biotechnology's (PBYI) Q3 2024 earnings call?

You can access the call by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international), or view the live webcast on Puma Biotechnology's website investor section.

How long will Puma Biotechnology's (PBYI) Q3 2024 earnings call replay be available?

The replay of the Q3 2024 earnings call will be archived on Puma Biotechnology's website for 90 days.

PUMA BIOTECHNOLOGY INC

NASDAQ:PBYI

PBYI Rankings

PBYI Latest News

PBYI Stock Data

134.01M
38.59M
15.14%
67.73%
6.5%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
LOS ANGELES